Maryland, USA–based glycobiology specialist GlycoMimetics (Nasdaq: GLYC) has seen its share price fall around 80% after the failure of a Phase III trial.
The company is hoping to develop novel therapies for cancer and inflammatory diseases, based on research into the structure and biology of saccharides, or carbohydrates.
Top-line results from the global trial of uproleselan in relapsing/remitting acute myeloid leukemia (AML) show no statistically-significant improvement in overall survival (OS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze